STRATEGIC ALLIANCES AND RESEARCH CONTRACTS (Detail Textuals) - Novartis - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Feb. 28, 2014	Jan. 31, 2010	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2011	Dec. 31, 2010	Oct. 31, 2014	Aug. 31, 2010
Strategic Alliances Disclosure [Line Items]
Non-refundable upfront license fee		$ 5.0
Value of common stock purchased		2.0
Fair value of common stock purchased		3.3
Revenue to be recognized from the non-refundable upfront license fee		3.7
Upfront payment received for research			$ 0.2	$ 0.2
Milestones payments receivable		206.6
Milestones payments receivable for achievement of preclinical development activities		0.6
Milestones payments receivable for achievement of clinical milestones		26.0	21.0
Milestones payments receivable for receipt of regulatory approvals		45.0	45.0
Milestones payments receivable for achievement sales milestones		$ 135.0	135.0
Milestone payment received in successful completion of preclinical development activities	$ 2.0				$ 0.3	$ 0.3
Milestone triggered on first patient dosed							$ 3.0
Amount receivable under manufacture clinical trial material								$ 14.9
Amount recognized from services performed under this new agreement			$ 0.2	$ 0.3